Rsv vaccine

Rsv vaccine has been studied in 6 papers since 2022: 1 observational study in people, 5 reviews; 2 in the past year. The newest paper, Jul 3, 2026: “The role of immunosenescence and chronic medical conditions on the immune response to respiratory syncytial virus in older individuals”.

Intervention

6 papers study it7 findingsUpdated

See all 6 papers on rsv vaccine

At a glance

The findings reach people, from one lab or study. 1 lab in 1 country; 1 trial, none about aging.

“The vaccine cohort was associated with lower odds of MACCE (OR 0.22; 0.15-0.34; p<0.0001)”
Real-World Cardiorespiratory Impact of Respiratory Syncytial Virus (RSV) Vaccination in the USA: A Retrospective Propensity-Matched AnalysisAHA Scientific Sessions 2025 abstract2025doi:10.1161/circ.152.suppl_3.4366407

None of its findings points the other way.

Humans: a single group. Cells, worms or flies and mice: nothing yet.
  • 1 lab in 1 country
  • 1 trial, none about aging
  • Funder: National Institute of Allergy and Infectious Diseases
  • Humans1

What did studies of rsv vaccine find?

2

Studies of rsv vaccine measured 2 outcomes: ischemic stroke and respiratory syncytial virus infection.

Ischemic stroke

no changein humans1

1 study
  1. Rsv vaccine was not clearly linked with ischemic stroke in humans.

    “Ischemic stroke did not reach significance at any interval.”

    Humans

    Real-World Cardiorespiratory Impact of Respiratory Syncytial Virus (RSV) Vaccination in the USA: A Retrospective Propensity-Matched Analysis

    AHA Scientific Sessions 2025 abstract

More on Ischemic stroke

Respiratory syncytial virus infection

downin humans1

1 study
  1. Rsv vaccine protects against respiratory syncytial virus infection in humans (older adults).

    “Three new RSV vaccines now have published data for two seasons, and while direct comparison is not possible due to differences in the timing, methodology and populations studies, all show good efficacy”

    Reviewolder adults

    Respiratory syncytial virus pulmonary infections in adults - disease burden and prevention

    Current opinion in pulmonary medicine

More on Respiratory syncytial virus infection

What is rsv vaccine linked with?

5

Studies link rsv vaccine with 5 measures, among them dementia, heart failure and myocardial infarction.

Dementia

downin humans1

1 study
  1. Rsv vaccine lowers the risk of dementia in humans.

    “immunization with the adjuvanted RSV vaccine, also containing AS01, was shown to reduce risk of dementia.”

    Review

    Infection, vaccination and risk of dementia: a proposed immunological model

    Frontiers in immunology

More on Dementia

Heart failure

downin humans1OR 0.32

1 study
  1. Rsv vaccine is linked with a lower risk of heart failure in humans (OR 0.32, 95% CI 0.19-0.55, p<0.0001).

    “heart failure (OR 0.32; 0.19-0.55; p<0.0001)”

    Humans

    Real-World Cardiorespiratory Impact of Respiratory Syncytial Virus (RSV) Vaccination in the USA: A Retrospective Propensity-Matched Analysis

    AHA Scientific Sessions 2025 abstract

More on Heart failure

Myocardial infarction

downin humans1OR 0.15

1 study
  1. Rsv vaccine is linked with a lower risk of myocardial infarction in humans (OR 0.15, 95% CI 0.08-0.31, p<0.0001).

    “acute MI (OR 0.15; 0.08-0.31; p<0.0001)”

    Humans

    Real-World Cardiorespiratory Impact of Respiratory Syncytial Virus (RSV) Vaccination in the USA: A Retrospective Propensity-Matched Analysis

    AHA Scientific Sessions 2025 abstract

More on Myocardial infarction

Mortality

downin humans1OR 0.16

1 study
  1. Rsv vaccine is linked with a lower risk of mortality in humans (OR 0.16, 95% CI 0.09-0.27, p<0.0001).

    “all-cause mortality (OR 0.16; 0.09-0.27; p<0.0001)”

    Humans

    Real-World Cardiorespiratory Impact of Respiratory Syncytial Virus (RSV) Vaccination in the USA: A Retrospective Propensity-Matched Analysis

    AHA Scientific Sessions 2025 abstract

Major adverse cardiovascular and cerebrovascular events

downin humans1OR 0.22

1 study
  1. Rsv vaccine is linked with a lower risk of major adverse cardiovascular and cerebrovascular events in humans (OR 0.22, 95% CI 0.15-0.34, p<0.0001).

    “The vaccine cohort was associated with lower odds of MACCE (OR 0.22; 0.15-0.34; p<0.0001)”

    Humans

    Real-World Cardiorespiratory Impact of Respiratory Syncytial Virus (RSV) Vaccination in the USA: A Retrospective Propensity-Matched Analysis

    AHA Scientific Sessions 2025 abstract

Trial sponsors

Funding

1 grant since 2018

National Institute of Allergy and Infectious Diseases$2.9M

Latest

Dec 2025: 0Jan 2026: 0Feb 2026: 0Mar 2026: 1Apr 2026: 0May 2026: 0Jun 2026: 0Jul 2026: 1Aug 2026: 0Sep 2026: 0Oct 2026: 0Nov 2026: 02 papers in 12 months